2023 Illinois Compiled Statutes › Chapter 410 - PUBLIC HEALTH › 410 ILCS 715/ - Illinois Drug Reuse Opportunity Program Act

(410 ILCS 715/1)
Sec. 1. Short title. This Act may be cited as the Illinois Drug Reuse Opportunity Program Act.
(Source: P.A. 102-389, eff. 1-1-22.)
(410 ILCS 715/5)
Sec. 5. Definitions. In this Act:
"Controlled substance" means a drug, substance, or immediate precursor in Schedules I through V of 21 CFR 1308.
"Dispense" has the same meaning as defined in Section 3 of the Pharmacy Practice Act.
"Donor" means any person, including an individual member of the public, or any entity legally authorized to possess medicine, including, but not limited to, a wholesaler or distributor, third party logistic provider, pharmacy, dispenser, clinic, surgical or health center, detention and rehabilitation center, jail, prison laboratory, medical or pharmacy school, prescriber or other health care professional, long-term care facility, or healthcare facility. "Donor" includes government agencies and entities that are federally authorized to possess medicine, including, but not limited to, drug manufacturers, repackagers, relabelers, outsourcing facilities, health care facilities operated by the U.S. Department of Veterans Affairs, and prisons.
"Drug" means a prescription drug, over-the-counter drug, or supplies needed to administer a prescription or over-the-counter drug.
"Eligible patient" means an individual:
(1) with a prescription for the drug, if a     prescription is required to dispense the drug, or who reports symptoms treated by the drug if the drug is over-the-counter; and
(2) who is registered with the drug's manufacturer in     accordance with federal Food and Drug Administration requirements, if the registration is required to dispense the drug.
"Manufacturer" has the same meaning as defined in Section 15 of the Wholesale Drug Distribution Licensing Act.
"Pharmacist" means an individual licensed to engage in the practice of pharmacy under the Pharmacy Practice Act or licensed to engage in the practice of pharmacy in another state.
"Practitioner" means a person licensed in this State to dispense or administer drugs or who is licensed in another state as a person authorized to dispense or administer drugs.
"Prescription drug" means any prescribed drug that may be legally dispensed by a pharmacy. "Prescription drug" does not include a drug for the treatment of cancer that can only be dispensed to a patient registered with the drug manufacturer in accordance with the federal Food and Drug Administration's requirements.
"Priority patient" means an eligible patient who is an Illinois resident and who is indigent, uninsured, underinsured, or enrolled in a public health benefits program.
"Recipient" means any person or entity legally authorized to possess medicine with a license or permit in the state in which the person or entity is located, including, but not limited to, a wholesaler or distributor, reverse distributor, repackager, hospital, pharmacy, or clinic.
"Returns processor" has the same meaning as defined in paragraph (18) of 21 U.S.C. 360eee. "Returns processor" includes, but is not limited to, a reverse distributor.
"Unopened tamper-evident packaging" has the same meaning as defined in the United States Pharmacopeia (USP) General Chapter 659, Packaging and Storage Requirements, including, but not limited to, unopened unit-dose, multiple-dose, immediate, secondary, and tertiary packaging.
(Source: P.A. 102-389, eff. 1-1-22.)
(410 ILCS 715/10)
Sec. 10. Donating and receiving drugs.  Notwithstanding any other law or rule, donors may donate drugs to recipients and recipients may receive donated drugs from donors. Recipients shall only dispense or administer drugs to eligible patients as described in Section 20, further donate drugs to another recipient as described in Section 30, or dispose of drugs as described in Section 35.
(Source: P.A. 102-389, eff. 1-1-22.)
(410 ILCS 715/15)
Sec. 15. Cost-free provision of drugs.  Drugs donated for use under this Act are considered nonsaleable. When dispensing a drug to an eligible patient, the recipient must do so at no cost to the eligible patient, except that a uniform reasonable handling fee may be charged. The handling fee may not exceed the direct or indirect cost to the recipient of providing the drug. Charging the fee does not constitute reselling.
(Source: P.A. 102-389, eff. 1-1-22.)
(410 ILCS 715/20)
Sec. 20. Requirements for dispensing drugs; priority.
(a) A recipient may only dispense or administer a prescription drug or provide an over-the-counter drug:
(1) if the recipient is otherwise permitted by law to     dispense or administer the drug;
(2) that meets the requirements in Section 25;
(3) that is repackaged into a new container or is in     its original container with all previous patient information redacted or removed;
(4) that is properly labeled in accordance with the     rules and regulations of the Board of Pharmacy;
(5) that has an expiration or beyond-use date brought     forward from the donated prescription drug or over-the-counter drug that will not expire before the use by the eligible patient based on the prescribing practitioner's directions for use or, for over-the-counter medicine, on the package's label; and
(6) that is not adulterated or misbranded, as     determined by a pharmacist or practitioner.
(b) Recipients shall, to the greatest extent practicable, dispense drugs received under this Act to priority patients.
(Source: P.A. 102-389, eff. 1-1-22.)
(410 ILCS 715/25)
Sec. 25. Requirements for accepting drugs.  A drug received but not yet accepted into inventory shall be kept in a separate designated area. A drug may be accepted under this Act only if all of the following requirements are met:
(1) The drug is in unopened tamper-evident packaging     or has been repackaged according to Section 30.
(2) The drug is not expired.
(3) The drug is not a controlled substance.
(4) The recipient maintains a written or electronic     record of a donation made under this Act consisting of the name, strength, and quantity of each accepted drug and the name, address, and telephone number of the donor, unless a recipient is further donating to a recipient under common ownership or common control. Notwithstanding any other law or rule, no other record of a donation is required.
(5) The donor has removed or redacted any patient     name and prescription number and any other patient identifying information on the drug or otherwise maintains patient confidentiality by executing a confidentiality agreement with the recipient according to all State and federal medical patient privacy laws, rules, or regulations.
(6) The drug has a method recognized by the United     States Pharmacopeia to detect improper temperature variations if the drug requires temperature control other than room temperature storage.
(Source: P.A. 102-389, eff. 1-1-22.)
(410 ILCS 715/30)
Sec. 30. Donating and repackaging.  Notwithstanding any other law or rule, a recipient may:
(1) further donate drugs to another recipient;
(2) repackage donated drugs as necessary for storage,     dispensing, administration, or transfers in accordance with the following:
(A) repackaged medicine shall be labeled with the         drug's name, strength, and expiration date, and shall be kept in a separate designated area until inspected and initialed by a pharmacist, practitioner, or a pharmacy technician; and
(B) if multiple packaged donated medicines with         varied expiration dates are repackaged together, the shortest expiration date shall be used; and
(3) replenish a drug of the same drug name and     strength previously dispensed or administered to an eligible patient in accordance with Section 340B of the federal Public Health Service Act.
(Source: P.A. 102-389, eff. 1-1-22.)
(410 ILCS 715/35)
Sec. 35. Disposition of drugs.  A donated drug that does not meet the requirements of Section 25 must be disposed of by returning it to the donor, destroying it by an incinerator, medical waste hauler, or other lawful method, or transferring it to a returns processor.  A record of disposal shall consist of the disposal method, the date of disposal, and the name and quantity of the drug disposed of.  Notwithstanding any other law or rule, no other record of disposal shall be required.
(Source: P.A. 102-389, eff. 1-1-22.)
(410 ILCS 715/40)
Sec. 40. Participation not required.  Nothing in this Act requires that a pharmacy or pharmacist be a recipient of drugs under this Act.
(Source: P.A. 102-389, eff. 1-1-22.)
(410 ILCS 715/45)
Sec. 45. Recordkeeping requirements. When performing any action associated with a program under this Act or otherwise processing a donated drug for tax, manufacturer, or other credit, a recipient shall be considered to be acting as a returns processor and shall comply with all recordkeeping requirements for nonsaleable returns under federal law.
(Source: P.A. 102-389, eff. 1-1-22.)
(410 ILCS 715/50)
Sec. 50. Change of ownership.  A donation or other transfer of possession or control of a drug under this Act shall not be construed as a change of ownership unless it is specified as such by the recipient. If a record of the donation's transaction information or history is required, the history shall begin with the donor of the drug,  include all prior donations, and, if the drug was previously dispensed, only include drug information required to be on the patient label in accordance with the Board of Pharmacy's rules and regulations.
(Source: P.A. 102-389, eff. 1-1-22.)
(410 ILCS 715/55)
Sec. 55. Retention of records. All records required under this Act shall be retained in physical or electronic format and on or off the recipient's premises for a period of 6 years. Donors or recipients may contract with one another or a third party to create or maintain records on each other's behalf. An identifier, such as a serial number or bar code, may be used in place of any or all information required by a record or label pursuant to this Act if it allows for such information to be readily retrievable.  Upon request by a State or federal regulatory agency, the identifier used for requested records shall be replaced with the original information. An identifier shall not be used on patient labels when dispensing or administering a drug.
(Source: P.A. 102-389, eff. 1-1-22.)
(410 ILCS 715/60)
Sec. 60. Authority.  This Act supersedes any inconsistent law or rule for activities conducted under this Act.
(Source: P.A. 102-389, eff. 1-1-22.)
(410 ILCS 715/65)
Sec. 65. Immunity.
(a) Except as provided in subsection (b), no manufacturer, donor, or recipient shall be liable in any criminal or civil action, or be subject to professional discipline, for activities solely and directly attributable to donating, receiving, or dispensing drugs under this Act.
(b) The immunity provided in subsection (a) shall not apply:
(1) if it is shown that the act or omission was an     unreasonable, willful, wanton, or reckless act;
(2) if it is shown that the person or entity knew or     should have known that the donated drug was adulterated or misbranded; or
(3) to acts or omissions outside the scope of a     program under this Act.
(Source: P.A. 102-389, eff. 1-1-22.)
(410 ILCS 715/90)
Sec. 90. (Amendatory provisions; text omitted).
(Source: P.A. 102-389, eff. 1-1-22; text omitted.)
(410 ILCS 715/95)
Sec. 95. (Amendatory provisions; text omitted).
(Source: P.A. 102-389, eff. 1-1-22; text omitted.)
(410 ILCS 715/100)
Sec. 100. (Amendatory provisions; text omitted).
(Source: P.A. 102-389, eff. 1-1-22; text omitted.)
(410 ILCS 715/105)
Sec. 105. (Amendatory provisions; text omitted).
(Source: P.A. 102-389, eff. 1-1-22; text omitted.)
(410 ILCS 715/110)
Sec. 110. (Amendatory provisions; text omitted).
(Source: P.A. 102-389, eff. 1-1-22; text omitted.)
(410 ILCS 715/115)
Sec. 115. (Amendatory provisions; text omitted).
(Source: P.A. 102-389, eff. 1-1-22; text omitted.)